Enterprise Value to EBITDA Ratio: Fate Therapeutics, Inc. (FATE)
Fate Therapeutics, Inc. (FATE) relies on an extensive network of cryogenic hubs for the secure delivery of cells, and plans to generate primary revenue through payments for high-tech treatments from insurance funds and medical centers. This chart demonstrates an EV/EBITDA ratio of 0.00. Fate Therapeutics, Inc. (FATE) maintains its status as a pioneer in the development of iPSC therapy, which ensures deep trust in the brand from both the medical community and investors.
Financial and market metric breakdowns for fatetherapeutics.com (FATE)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Fate Therapeutics, Inc.|FATE - Long-Term Liabilities to Equity|Short-Term Debt to Capital Fate Therapeutics|FATE - Company Aggregate Debts|Debt to Book Value Fate Pharma|FATE - Amount of Long-Term Liabilities|Company Short-Term Debts Fate Therapeutics|Quick Liquidity Indicator fatetherapeutics.com
- business earnings and investment ratios data:
FATE - Final Profit|Future Profit Fate Therapeutics, Inc.|FATE - Market Price to Net Income Ratio|Forward P/E Multiple Fate Therapeutics, Inc.|FATE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Fate Pharma|FATE - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Fate Therapeutics|FATE - Earnings per share for the trailing year|Quarterly EPS earnings growth fatetherapeutics.com|FATE - Earnings growth in current year|Net earnings per share growth forecast for next year Fate Therapeutics, Inc.
Fundamental company analysis:Fate Therapeutics Corp (FATE)
The EV/EBITDA multiple compares the total enterprise value, including debt, to operating profit before interest, taxes, depreciation, and amortization. This metric demonstrates the actual value of the asset, stripped of the influence of capital structure. By analyzing the EV/EBITDA ratio of Fate Therapeutics, Inc. (FATE) on the chart, an investor sees the immediate market reaction to financial reports. For Fate Therapeutics, Inc. (FATE), this is a critical efficiency indicator amid the fierce technological battle for leadership in cell therapy.
Competing companies
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|DCTH: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL: Enterprise Value to EBITDA Ratio|Accuray, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SLS: EV/EBITDA Multiple|Company Value to EBITDA actuatetherapeutics.com (ACTU)|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TARA (Protara)|Enterprise Value to Operating Income Before Depreciation Ratio WHWK|EV/EBITDA Multiple TCRX (TScan Therapeutics, Inc.)|Business Value to Operating Income Before Depreciation CSBR|XBiotech USA - EV/EBITDA Multiple|Company Value to EBITDA CEL-SCI Corporation|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radiopharm Theranostics Ltd - Business Value to Operating Income Before Depreciation|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Adlai Nortye Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Company Value to EBITDA|MURA: Enterprise Value to EBITDA Ratio|KAPA - EV/EBITDA Multiple|OKUR (onkuretherapeutics.com) - Enterprise Value to EBITDA Ratio|GDTC: Enterprise Value to Operating Income Before Depreciation Ratio|CRIS (Curis Inc.) - EV/EBITDA Multiple|Apollomics Corp (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THAR|Enterprise Value to EBITDA Ratio advanbiomed.com ADVB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|SBFM: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIO (Xenetic Biosciences)|SLRX: EV/EBITDA Multiple|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|Enterprise Value to Operating Income Before Depreciation BGNE (BeiGene Ltd.)|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|iCAD - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Ikena Oncology Inc. (IKNA)|Notable Labs - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio VIRX|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio AAPGV
